Dublin, May 29, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Cancer Metabolism Based Therapeutics, 2017-2030" report to their offering. Cancer metabolism is based on the principle that cancer cells, as compared to normal cells, have different metabolic activities in order to support their enhanced energy and anabolic requirements. The pioneering discovery by Otto Warburg in the middle of the 20th century led to the observation that metabolic activity in tumor tissues leads to a ten-fold increase in production of lactate (from glucose) under aerobic conditions. This revelation generated a significant interest and led industry stakeholders to target metabolic pathways in an effort to find the treatment of cancer. In addition, several academic players have also initiated studies to explore the functional consequences of alterations in various metabolic pathways. The idea behind therapeutic strategies that target cancer metabolism is to limit/modulate the supply of crucial nutrients in cancer cells in order to induce cell death. Over the years, experimental and conceptual advances in this field have resulted in a better understanding of the role of metabolic pathways for the treatment of cancer. Owing to the complex nature of these pathways, innovation in this domain has been gradual. However, the knowledge that metabolic adaptations in cancer cells promote their malignant properties has led to the development of novel therapeutic approaches for cancer treatment; selective inhibition of altered metabolic pathways in cancer cells is believed to be a highly promising approach. Currently, there are several molecules that are under preclinical and clinical evaluation. Extensive research is currently being carried out to explore the potential of certain enzymes of metabolic pathways to act as targets for the treatment of cancer. The alterations in metabolic pathways in cancer cells are often mediated by mutations in oncogenes and cell signaling pathways. However, with the recognition of specific enzymes within each metabolic pathway, it is anticipated that drugs targeting these enzymes are likely to have high efficacy in treating cancer with minimal side-effects. The "Cancer Metabolism Based Therapeutics Market, 2017-2030" report provides an extensive study on the current landscape of the emerging pipeline of novel drugs that target metabolic pathways in cancer cells and offers a comprehensive discussion on the likely future potential.
Despite the fact that the field of cancer metabolism therapeutics is still in early stages, there are many active players in this area. A larger proportion of players (on the basis of number of molecules) are small-sized and start-up companies. In fact, well-known big pharma companies have come together with smaller players to support discovery and development of such therapies. Our research indicates that there are several players with mid/late-stage clinical candidates that are likely to enter the market in the coming decade; examples include Agios Pharmaceuticals, Celgene, Polaris Group, Bio-Cancer Treatment International, BERG Health, Cornerstone Pharmaceuticals, Taiho Pharmaceutical, Novartis and 3-V Biosciences.
The primary focus is on drugs that lead to metabolic reprogramming in cancer cells by altering/inhibiting the activity of key enzymes/transporters that are a part of glucose metabolism, amino acid metabolism, TCA cycle, lipid metabolism, nucleotide metabolism and pentose phosphate pathway. The scope includes novel products that are being specifically developed to target altered metabolic pathways and key enzymes/amino acids involved in the metabolism of cancer cells. Examples of such enzymes/amino acids include isocitrate dehydrogenase 1 mutant (IDH 1), arginine, glutamine, MTH1, L-type amino acid transporter 1 (LAT1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB3), choline kinase (ChoK), glucose transporter-1 (Glut-1) and hexokinase II. Specifically, certain drugs based on amino acid metabolism are being developed under the class of immuno-oncology drugs; these have been excluded from the scope of this document. The overall pipeline comprises of 48 molecules that are under development for the treatment of a variety of oncological indications. Of these, 20 molecules are undergoing clinical evaluation while others (28) are in discovery/preclinical stages. This unexploited and promising market has its hopes pinned on multiple start-ups and small-sized companies, which have received significant financial support from strategic investors and venture capital firms in the recent past.
One of the key objectives of this report was to understand the current activity and the future potential of the market. The study provides a detailed market forecast and opportunity analysis from 2017 to 2030. The research, analysis and insights presented in this report are backed by a detailed understanding of the therapies targeting cancer metabolism and other targets closely associated with them. To account for uncertaintiesassociated with the development of novel therapeutics and add robustness to our model, we have provided three scenarios for our market forecast, namely the conservative, base and optimistic scenarios. All actual figures have been sourced and analyzed from publicly available information forums and from primary research. All financial figures mentioned in this report are in USD, unless otherwise specified. Key Topics Covered: 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Cellular Metabolism: An Introduction 3.3. Cancer Cell Metabolism: An Introduction 3.4. Cancer Cell Metabolism: History and Evolution 3.5. Altered Metabolic Pathways in Cancer Cells 3.5.1. Glucose Metabolism 3.5.2. TCA Cycle 3.5.3. Amino Acid Metabolism 3.5.4. Nucleotide Metabolism 3.5.5. Pentose Phosphate Pathway 3.5.6. Lipid Metabolism 3.6. Challenges Associated with Targeting Metabolic Pathways 3.7. Targeting Altered Metabolic Pathways for Cancer Treatment 4. MARKET OVERVIEW 4.1. Chapter Overview 4.2. Cancer Metabolism Based Therapeutics: Clinical Pipeline 4.3. Cancer Metabolism Based Therapeutics: Preclinical Pipeline 4.4. Cancer Metabolism Based Therapeutics: Distribution by Phase of Development 4.5. Cancer Metabolism Based Therapeutics: Distribution by Targeted Metabolic Pathway 4.6. Cancer Metabolism Based Therapeutics: Distribution by Target 4.7. Cancer Metabolism Based Therapeutics: Distribution by Type of Molecule 4.8. Cancer Metabolism Based Therapeutics: Distribution by Therapeutic Area 4.9. Cancer Metabolism Based Therapeutics: Distribution by Indication 4.10. Cancer Metabolism Based Therapeutics: Distribution by Route of Administration 4.11. Cancer Metabolism Based Therapeutics: Distribution by Key Players 4.12. Cancer Metabolism Based Therapeutics: Distribution by Headquarters of Developers 4.13. Cancer Metabolism Based Therapeutics: Role of Non-Industry Players 5. DRUG PROFILES 5.1. Chapter Overview 5.2. Enasidenib/AG-221 (Agios Pharmaceuticals) 5.2.1. Overview 5.2.2. Mechanism of Action 5.2.3. Current Status of Development 5.2.4. Clinical Studies 5.2.5. Preclinical/Clinical Findings 5.2.6. Agios Pharmaceuticals 5.3. Ivosidenib/AG-120 (Agios Pharmaceuticals) 5.3.1. Overview 5.3.2. Mechanism of Action 5.3.3. Current Status of Development 5.3.4. Clinical Studies 5.3.5. Preclinical/Clinical Findings 5.3.6. Agios Pharmaceuticals 5.4. ADI-PEG 20 (Polaris Group) 5.4.1. Overview 5.4.2. Mechanism of Action 5.4.3. Current Status of Development 5.4.4. Clinical Studies 5.4.5. Preclinical/Clinical Findings 5.4.6. Polaris Group 5.5. BCT-100 (Bio-Cancer Treatment International) 5.5.1. Overview 5.5.2. Mechanism of Action 5.5.3. Current Status of Development 5.5.4. Clinical Studies 5.5.5. Preclinical/Clinical Findings 5.5.6. Bio-Cancer Treatment International 5.6. BPM 31510 (BERG Health) 5.6.1. Overview 5.6.2. Mechanism of Action 5.6.3. Current Status of Development 5.6.4. Clinical Studies 5.6.5. Preclinical/Clinical Findings 5.6.5.1. Preclinical Data 5.6.5.2. Clinical Data 5.6.6. BERG Health 5.6.6.1. Overview 5.6.6.2. Technology Platform: Interrogative Biology® 5.6.6.3. Future Outlook 5.7. CPI-613 (Cornerstone Pharmaceuticals) 5.7.1. Overview 5.7.2. Mechanism of Action 5.7.3. Current Status of Development 5.7.4. Clinical Studies 5.7.5. Preclinical/Clinical Findings 5.7.6. Cornerstone Pharmaceuticals 5.8. TAS-114 (Taiho Pharmaceutical) 5.8.1. Overview 5.8.2. Mechanism of Action 5.8.3. Current Status of Development 5.8.4. Clinical Studies 5.8.5. Preclinical/Clinical Findings 5.8.6. Taiho Pharmaceutical 5.9. IDH305 (Novartis) 5.9.1. Overview 5.9.2. Mechanism of Action 5.9.3. Current Status of Development 5.9.4. Clinical Studies 5.9.5. Preclinical/Clinical Findings 5.9.6. Novartis 5.10. TVB 2640 (3-V Biosciences) 5.10.1. Overview 5.10.2. Mechanism of Action 5.10.3. Current Status of Development 5.10.4. Clinical Studies 5.10.5. Preclinical/Clinical Findings 5.10.6. 3-V Biosciences 6. MARKET FORECAST AND OPPORTUNITY ANALYSIS 6.1. Chapter Overview 6.2. Scope and Limitations 6.3. Forecast Methodology 6.4. Overall Cancer Metabolism Based Therapeutics Market (USD Million) 6.5. Cancer Metabolism Based Therapeutics Market: Individual Drug Forecasts (USD Million) 6.5.1. Enasidenib (Agios Pharmaceuticals) 6.5.2. Ivosidenib (Agios Pharmaceuticals) 6.5.3. ADI-PEG 20 (Polaris Group) 6.5.4. BPM 31510 (BERG Health) 6.5.5. CPI-613 (Cornerstone Pharmaceuticals) 6.5.6. BCT-100 (Bio-Cancer Treatment International) 6.5.7. IDH305 (Novartis) 6.5.8. TAS-114 (Taiho Pharmaceutical) 6.5.9. TBV-2640 (3-V Biosciences) 7. VENTURE CAPITAL INTEREST 7.1. Chapter Overview 7.2. Cancer Metabolism Based Therapeutics: List of Funding Instances 7.2.1. Cancer Metabolism Based Therapeutics: Cumulative Number of Investments by Year, Pre 2010-2017 7.2.2. Cancer Metabolism Based Therapeutics: Cumulative Amount Invested by Year, Pre 2010-2017 (USD Million) 7.2.3. Cancer Metabolism Based Therapeutics: Distribution of Funding Instances by Type of Funding 7.2.4. Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Industry Players 7.2.5. Cancer Metabolism Based Therapeutics: Funding Instances, Most Active Venture Capital Firms/Investors 8. PARTNERSHIPS AND COLLABORATIONS 8.1. Chapter Overview 8.2. Partnership Models 8.3. Cancer Metabolism Based Therapeutics: Recent Partnerships 9. KEY INSIGHTS 9.1. Chapter Overview 9.2. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Developer Landscape 9.3. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Targeted Metabolic Pathway, Phase of Development and Type of Molecule 9.4. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Geographical Presence of Companies 9.5. Cancer Metabolism Based Therapeutics: Pipeline Analysis by Popularity of Metabolic Enzymes/Targets 10. CONCLUSION 10.1. Growing Understanding of Tumor Associated Metabolic Alterations has Advanced the Field of Cancer Metabolism 10.2. Commercialization of Late-Stage Drugs and Advancement of Discovery/Preclinical Candidates in the Near Future is Likely to Sustain the Momentum 10.3. Amongst Various Metabolic Pathways, Amino Acid Metabolism and Glucose Metabolism Have Been Most Widely Researched 10.4. Small Pharmaceutical Companies are Emerging as Key Players; Research is Heavily Concentrated in the US and Parts of Europe 10.5. Growing Partnerships and Venture Capital Support are Indicative of Lucrative Future Potential 10.6. Once Approved, Cancer Metabolism Based Therapeutics are Poised to Achieve an Accelerated Growth 11. INTERVIEW TRANSCRIPTS 11.1. Chapter Overview 11.2. Raul Mostoslavsky, Associate Professor, Medicine, Harvard Medical School 11.3. Magdalena Marciniak, Business Alliance Manager, Selvita S.A. 12. APPENDIX 1: TABULATED DATA 13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned - 2M Companies - 3-V Biosciences - Abbott - Accelerate Brain Cancer Cure - Adage Capital Partners - Ade Capital Sodical SCR - Admune Therapeutics - Advanced Cancer Therapeutics - Advanced Technology Ventures - Aeglea BioTherapeutics - Agios Pharmaceuticals - Aju Tech - Alexandria Venture Investments - Ally Bridge Group - Althea Partners - American Association for Cancer Research - American Society for Radiation Oncology - American Society of Clinical Oncology - American Society of Hematology - ARCH Venture Partners - Arkin Holdings - Astellas Venture Management - AstraZeneca - Atlas Venture - Barts Cancer Institute - Bayer - Becton Dickinson - BERG Health - BIND Therapeutics - Bio-Cancer Treatment International - BioMed X - Boehringer Ingelheim Venture Fund - Boston College - Bristol Myers Squibb - Calithera Biosciences - Cancer Research Technology - Cancer Research UK - Celgene - Chinese University of Hong Kong - Ciba-Geigy - Clave Mayor - Cloud Pharmaceuticals - Commonwealth Capital Ventures - Conegliano Ventures - Cornerstone Pharmaceuticals - Cowen Group - CRB Inverbio - Daiichi Sankyo - Dana-Farber Cancer Institute - Delphi Ventures - DesigneRx Pharmaceuticals - Emory University - Encore Vision - European Hematology Association - European Medicines Agency - European Molecular Biology Laboratory - European Organisation for Research and Treatment of Cancer - European Society of Medical Oncology - Flagship Ventures - Food and Drug Administration - FORMA Therapeutics - Foundation Medicine - Genentech - German Cancer Research Center - Gilead Sciences - GNTech - Grifols - Harvard Medical School - Hong Kong Department of Health - Horizon Discovery - IDT Corporation - ImmunoMet Therapeutics - Informa - International Mesothelioma Interest Group - IOmet Pharma - J Pharma - Janssen Biotech - Jennison Associates - Kancera - Kantar Health - Karolinska Institutet - KBI Biopharma - Kentucky Science and Technology Corporation - Kleiner Perkins Caufield & Byers - Kyushu University - Lightstone Ventures - Lilly Ventures - Lo Ka Chung Centre for Natural Anti-Cancer Drug Development - Longwood Fund - Louisiana State University - Ludwig Institute for Cancer Research - Mary Crowley Cancer Research Centers - Massachusetts General Hospital Cancer Center - MD Anderson Cancer Center - Medical University of Vienna - Medidata Solutions - Memorial Sloan Kettering Cancer Center - Merck KGaA - Metabomed - MetaVest - Mirae Asset Venture Investment - Mission Bay Capital - Moleculin - Morgenthaler Ventures - MPM Capital - MS Ventures - National Cancer Institute - National Institutes of Health - New Enterprise Associates - New Medical Enzymes - New York University School of Medicine - Nimbus Therapeutics - Northwestern University - Novartis - Novartis Venture Fund - Novo - Ohio State University - Oncotherapeutics - OrbiMed - Ostuka Holdings - Partikula - Partners Innovation Fund - Pfizer - Polaris Group - Polaris Pharmaceuticals - Pontifax - Princeton University - Queen Mary Hospital - Quintiles - RA Capital Management - Raze Therapeutics - Rgenix - Rock Springs Capital - Rutgers Cancer Institute of New Jersey, Rutgers University - Sandoz - Selexys Pharmaceuticals - Selvita - Sofinnova Partners - Spinifex Pharmaceuticals - Sprint Bioscience - Stand Up To Cancer - Stanford University - Stanford University School of Medicine - Stockholm University - Sylvester Comprehensive Cancer Center - Taiho Oncology - Taiho Pharmaceutical - Taiho Ventures - TAVARGENIX - TDW Group - TDW Pharmaceuticals - Technion Research & Development Foundation - Telix Pharmaceuticals - The Abramson Family Foundation - The Chetrit Group - The Column Group - The Francis Crick Institute - The Hong Kong Polytechnic University - Therapeia - Third Rock Ventures - TPP Global Development - Translational Cancer Drugs (TCD) Pharma - University of Birmingham - University of Bologna - University of California - University of Chicago - University of Florida - University of Hong Kong - University of Kentucky - University of Louisville's James Graham Brown Cancer Center - University of Miami - University of Miami Leonard M. Miller School of Medicine - University of Michigan - University of Pennsylvania - University of Texas Health Science Center - University of Texas Southwestern Medical Center - US Venture Partners - UT Horizon Fund - Venrock - vTv Therapeutics - Wake Forest University - Weill Cornell Medical College - Wilson Sonsini Goodrich & Rosati - Windhover Information - Ziarco Group For more information about this report visit http://www.researchandmarkets.com/research/5h...metabolism
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Oncology Drugs
